China SXT Pharmaceuticals, Inc. (SXTC) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for China SXT Pharmaceuticals, Inc. (SXTC:NASDAQ), powered by AI.

Current Price
$2.57
P/E Ratio
-0.0
Market Cap
24,384
Sector
Healthcare
What is the China SXT Pharmaceuticals, Inc. stock price forecast?

China SXT Pharmaceuticals, Inc. is currently trading at $2.57. View real-time AI analysis on Alpha Lenz.

What is China SXT Pharmaceuticals, Inc. insider trading activity?

View the latest insider trading data for China SXT Pharmaceuticals, Inc. on Alpha Lenz.

What is China SXT Pharmaceuticals, Inc.'s P/E ratio?

China SXT Pharmaceuticals, Inc.'s P/E ratio is -0.0.

China SXT Pharmaceuticals, Inc.

NASDAQ · SXTC
$2.57+0.31(+13.72%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about China SXT Pharmaceuticals, Inc.'s future dividend policy...
Alpha Chat Insight

China SXT Pharmaceuticals, Inc. trades at a P/E of -0.0 (undervalued) with modest ROE of -22.5%.

Ask for details

Company Overview

China SXT Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on the development, production, and sale of Chinese traditional medicine products. The company primarily engages in the creation of Advanced and Directly-Oral Solutions of Traditional Chinese Medicine Pieces (TCMPs) and Fine TCMPs, aiming to modernize and enhance the accessibility of traditional formulations. China SXT Pharmaceuticals caters to a diverse customer base, including hospitals, pharmacies, and end-consumers, by providing herbal and plant-based remedies that are deeply rooted in centuries-old Chinese medical practices. Positioned in the healthcare and pharmaceuticals sector, the company's innovations not only serve the domestic Chinese market but also seek to establish a global presence in the growing field of alternative medicine. Headquartered in Taizhou Jiangsu, China, China SXT Pharmaceuticals, Inc. plays a significant role in bridging traditional healing methods with contemporary healthcare demands, by leveraging unique, time-tested product offerings in a modern pharmaceutical context.

CEOMr. Feng Zhou
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees75

Company Statistics

FY 2025

Profile

$24.38KMarket Cap
$1.74MRevenue
0.00Shares Out
75Employees

Margins

21.11%Gross
-147.80%EBITDA
-153.97%Operating
-189.77%Pre-Tax
-189.77%Net

Valuation

-0.01P/E
0.00P/B
0.01EV/Sales
6.64EV/EBITDA
-0.01P/FCF

Growth (CAGR)

-12.54%Rev 3Yr
-19.54%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-14.75%ROA
-22.50%ROE
-11.86%ROIC

Financial Health

$18.10MCash & Cash Equivalents
$-11.88MNet Debt
40.31%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

China SXT Pharmaceuticals, Inc. (ticker: SXTC) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 75 employees. Market cap is $24,384.

The current price is $2.57 with a P/E ratio of -0.01x and P/B of 0x.

ROE is -22.50% and operating margin is -153.97%. Annual revenue is $2M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
China SXT Pharmaceuticals, Inc. (SXTC) Stock Forecast 2026 $2.57 — Price, Financials & Analyst Targets | Alpha Lenz